Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

The HIV-1 Tat protein affects human CD4+ T-cell programing and activation, and favors the differentiation of naïve CD4+ T cells.

Nicoli F, Gallerani E, Sforza F, Finessi V, Chachage M, Geldmacher C, Cafaro A, Ensoli B, Caputo A, Gavioli R.

AIDS. 2018 Mar 13;32(5):575-581. doi: 10.1097/QAD.0000000000001734.

PMID:
29280760
2.

Rational Design of Nucleoside-Bile Acid Conjugates Incorporating a Triazole Moiety for Anticancer Evaluation and SAR Exploration.

Navacchia ML, Marchesi E, Mari L, Chinaglia N, Gallerani E, Gavioli R, Capobianco ML, Perrone D.

Molecules. 2017 Oct 12;22(10). pii: E1710. doi: 10.3390/molecules22101710.

3.

Solid lipid nanoparticles for the delivery of 1,3,5-triaza-7-phosphaadamantane (PTA) platinum (II) carboxylates.

Sguizzato M, Cortesi R, Gallerani E, Drechsler M, Marvelli L, Mariani P, Carducci F, Gavioli R, Esposito E, Bergamini P.

Mater Sci Eng C Mater Biol Appl. 2017 May 1;74:357-364. doi: 10.1016/j.msec.2016.12.020. Epub 2016 Dec 7.

PMID:
28254304
4.

AGHLDDLPGALSAL: A hemoglobin fragment potentially competing with albumin to bind transition metal ions.

Zamariola G, Watly J, Gallerani E, Gavioli R, Guerrini R, Kozlowski H, Remelli M.

J Inorg Biochem. 2016 Oct;163:301-310. doi: 10.1016/j.jinorgbio.2016.04.001. Epub 2016 Apr 8.

PMID:
27087285
5.

NO Photoreleaser-Deoxyadenosine and -Bile Acid Derivative Bioconjugates as Novel Potential Photochemotherapeutics.

Navacchia ML, Fraix A, Chinaglia N, Gallerani E, Perrone D, Cardile V, Graziano AC, Capobianco ML, Sortino S.

ACS Med Chem Lett. 2016 Aug 18;7(10):939-943. eCollection 2016 Oct 13.

6.

Systemic immunodominant CD8 responses with an effector-like phenotype are induced by intravaginal immunization with attenuated HSV vectors expressing HIV Tat and mediate protection against HSV infection.

Nicoli F, Gallerani E, Skarlis C, Sicurella M, Cafaro A, Ensoli B, Caputo A, Marconi PC, Gavioli R.

Vaccine. 2016 Apr 27;34(19):2216-24. doi: 10.1016/j.vaccine.2016.03.022. Epub 2016 Mar 19.

PMID:
27002499
7.

Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers.

Gross S, Lennerz V, Gallerani E, Mach N, Böhm S, Hess D, von Boehmer L, Knuth A, Ochsenbein A, Gnad-Vogt U, Forssmann U, Woelfel T, Kaempgen E.

Cancer Immunol Res. 2016 Jan;4(1):18-25. doi: 10.1158/2326-6066.CIR-15-0105. Epub 2015 Nov 12.

8.

Development and characterization of K562 cell clones expressing BCL11A-XL: Decreased hemoglobin production with fetal hemoglobin inducers and its rescue with mithramycin.

Finotti A, Gasparello J, Breveglieri G, Cosenza LC, Montagner G, Bresciani A, Altamura S, Bianchi N, Martini E, Gallerani E, Borgatti M, Gambari R.

Exp Hematol. 2015 Dec;43(12):1062-1071.e3. doi: 10.1016/j.exphem.2015.08.011. Epub 2015 Sep 3.

9.

Incorporation of Naked Peptide Nucleic Acids into Liposomes Leads to Fast and Efficient Delivery.

Avitabile C, Accardo A, Ringhieri P, Morelli G, Saviano M, Montagner G, Fabbri E, Gallerani E, Gambari R, Romanelli A.

Bioconjug Chem. 2015 Aug 19;26(8):1533-41. doi: 10.1021/acs.bioconjchem.5b00156. Epub 2015 Jul 30.

10.

Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.

Scotti A, Trapella C, Ferretti V, Gallerani E, Gavioli R, Marastoni M.

J Enzyme Inhib Med Chem. 2016;31(3):456-63. doi: 10.3109/14756366.2015.1037749. Epub 2015 May 5.

PMID:
25942361
11.

Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide.

Finessi V, Nicoli F, Gallerani E, Sforza F, Sicurella M, Cafaro A, Caputo A, Ensoli B, Gavioli R.

Hum Vaccin Immunother. 2015;11(6):1489-93. doi: 10.1080/21645515.2015.1016676.

12.

Phase-I dose finding and pharmacokinetic study of the novel hydrophilic camptothecin ST-1968 (namitecan) in patients with solid tumors.

Joerger M, Hess D, Delmonte A, Gallerani E, Barbieri P, Pace S, Sessa C.

Invest New Drugs. 2015 Apr;33(2):472-9. doi: 10.1007/s10637-015-0219-5. Epub 2015 Feb 20.

PMID:
25693886
13.

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair OM, Pistilli B, Warner E, Saloustros E, Perey L, Zaman K, Rabaglio M, Gelber S, Gelber RD, Goldhirsch A, Korde L, Azim HA Jr, Partridge AH.

Breast. 2015 Jun;24(3):201-7. doi: 10.1016/j.breast.2015.01.005. Epub 2015 Feb 4.

PMID:
25662412
14.

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).

Joerger M, Hess D, Delmonte A, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C.

Br J Clin Pharmacol. 2015 Jul;80(1):128-38. doi: 10.1111/bcp.12583. Epub 2015 Jun 3.

15.

Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study.

Moreno García V, Olmos D, Gomez-Roca C, Cassier PA, Morales-Barrera R, Del Conte G, Gallerani E, Brunetto AT, Schöffski P, Marsoni S, Schellens JH, Penel N, Voest E, Evans J, Plummer R, Wilson RH, Soria JC, Tabernero J, Verweij J, Kaye SB.

Clin Cancer Res. 2014 Nov 15;20(22):5663-71. doi: 10.1158/1078-0432.CCR-14-0719. Epub 2014 Sep 24.

16.

An attenuated herpes simplex virus type 1 (HSV1) encoding the HIV-1 Tat protein protects mice from a deadly mucosal HSV1 challenge.

Sicurella M, Nicoli F, Gallerani E, Volpi I, Berto E, Finessi V, Destro F, Manservigi R, Cafaro A, Ensoli B, Caputo A, Gavioli R, Marconi PC.

PLoS One. 2014 Jul 17;9(7):e100844. doi: 10.1371/journal.pone.0100844. eCollection 2014.

17.

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.

Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L.

Br J Cancer. 2014 Aug 12;111(4):651-9. doi: 10.1038/bjc.2014.345. Epub 2014 Jul 15.

18.

HIV-1 Tat affects the programming and functionality of human CD8⁺ T cells by modulating the expression of T-box transcription factors.

Sforza F, Nicoli F, Gallerani E, Finessi V, Reali E, Cafaro A, Caputo A, Ensoli B, Gavioli R.

AIDS. 2014 Jul 31;28(12):1729-38. doi: 10.1097/QAD.0000000000000315.

PMID:
24841128
19.

Estramustine phosphate sodium in heavily pretreated patients with metastatic breast cancer: a retrospective consecutive case series.

Aurilio G, Graffeo R, Bagnardi V, Nolè F, Adamoli L, Pagani O, Gallerani E, Ferrari B, Pruneri G, Goldhirsch A.

Int J Clin Oncol. 2015 Feb;20(1):90-4. doi: 10.1007/s10147-014-0694-2. Epub 2014 Apr 12.

PMID:
24722887
20.

Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database.

Cassier PA, Polivka V, Judson I, Soria JC, Penel N, Marsoni S, Verweij J, Schellens JH, Morales-Barrera R, Schöffski P, Voest EE, Gomez-Roca C, Evans TR, Plummer R, Gallerani E, Kaye SB, Olmos D.

Ann Oncol. 2014 Jun;25(6):1222-8. doi: 10.1093/annonc/mdu108. Epub 2014 Mar 7.

PMID:
24608201
21.

Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.

Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E.

Cancer Immunol Immunother. 2014 Apr;63(4):381-94. doi: 10.1007/s00262-013-1516-5. Epub 2014 Feb 2.

PMID:
24487961
22.

The HIV-1 Tat protein induces the activation of CD8+ T cells and affects in vivo the magnitude and kinetics of antiviral responses.

Nicoli F, Finessi V, Sicurella M, Rizzotto L, Gallerani E, Destro F, Cafaro A, Marconi P, Caputo A, Ensoli B, Gavioli R.

PLoS One. 2013 Nov 4;8(11):e77746. doi: 10.1371/journal.pone.0077746. eCollection 2013.

23.

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.

Sessa C, Del Conte G, Christinat A, Cresta S, Perotti A, Gallerani E, Lardelli P, Kahatt C, Alfaro V, Iglesias JL, Fernández-Teruel C, Gianni L.

Invest New Drugs. 2013 Oct;31(5):1236-43. doi: 10.1007/s10637-013-9942-y. Epub 2013 Mar 7.

PMID:
23467812
24.

A phase I study of the oral platinum agent satraplatin in combination with oral vinorelbine in patients with advanced solid malignancies.

Gallerani E, Cathomas R, Sessa C, Digena T, Bartosek AA, Dal Zotto L, von Moos R.

Onkologie. 2013;36(1-2):40-5. doi: 10.1159/000346671. Epub 2013 Jan 28.

PMID:
23429330
25.

T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.

Laurent J, Touvrey C, Gillessen S, Joffraud M, Vicari M, Bertrand C, Ongarello S, Liedert B, Gallerani E, Beck J, Omlin A, Sessa C, Quaratino S, Stupp R, Gnad-Vogt US, Speiser DE.

J Transl Med. 2013 Jan 7;11:5. doi: 10.1186/1479-5876-11-5.

26.

A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.

Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C.

Eur J Cancer. 2013 Jan;49(2):290-6. doi: 10.1016/j.ejca.2012.09.009. Epub 2012 Oct 8. Review.

PMID:
23058787
27.

A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours.

Gillessen S, Gnad-Vogt US, Gallerani E, Beck J, Sessa C, Omlin A, Mattiacci MR, Liedert B, Kramer D, Laurent J, Speiser DE, Stupp R.

Eur J Cancer. 2013 Jan;49(1):35-44. doi: 10.1016/j.ejca.2012.07.015. Epub 2012 Aug 20.

28.

Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.

Van Cutsem E, Tejpar S, Vanbeckevoort D, Peeters M, Humblet Y, Gelderblom H, Vermorken JB, Viret F, Glimelius B, Gallerani E, Hendlisz A, Cats A, Moehler M, Sagaert X, Vlassak S, Schlichting M, Ciardiello F.

J Clin Oncol. 2012 Aug 10;30(23):2861-8. doi: 10.1200/JCO.2011.40.9243. Epub 2012 Jul 2.

PMID:
22753904
29.

Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors.

Olmos D, A'hern RP, Marsoni S, Morales R, Gomez-Roca C, Verweij J, Voest EE, Schöffski P, Ang JE, Penel N, Schellens JH, Del Conte G, Brunetto AT, Evans TR, Wilson R, Gallerani E, Plummer R, Tabernero J, Soria JC, Kaye SB.

J Clin Oncol. 2012 Mar 20;30(9):996-1004. doi: 10.1200/JCO.2010.34.5074. Epub 2012 Feb 21.

PMID:
22355064
30.

Proteasome inhibitors induce the presentation of an Epstein-Barr virus nuclear antigen 1-derived cytotoxic T lymphocyte epitope in Burkitt's lymphoma cells.

Destro F, Sforza F, Sicurella M, Marescotti D, Gallerani E, Baldisserotto A, Marastoni M, Gavioli R.

Immunology. 2011 May;133(1):105-14. doi: 10.1111/j.1365-2567.2011.03416.x. Epub 2011 Feb 22.

31.

A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.

Gallerani E, Bauer J, Hess D, Boehm S, Droege C, Jeckelmann S, Miani M, Herrmann R, Marsoni S, Sperka S, Sessa C.

Acta Oncol. 2011 Oct;50(7):1105-10. doi: 10.3109/0284186X.2010.543697. Epub 2010 Dec 27.

PMID:
21184645
32.

Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis.

Garassino MC, Torri V, Michetti G, Lo Dico M, La Verde N, Aglione S, Mancuso A, Gallerani E, Galetta D, Martelli O, Collovà E, Fatigoni S, Ghidini A, Saggia C, Bareggi C, Rossi A, Farina G, Thatcher N, Blackhall F, Lorigan P, Califano R.

Lung Cancer. 2011 Jun;72(3):378-83. doi: 10.1016/j.lungcan.2010.09.009. Epub 2010 Oct 15.

PMID:
20950888
33.

Premedication with sublingual morphine sulphate in abdominal surgery.

Campiglia L, Cappellini I, Consales G, Borracci T, Vitali L, Gallerani E, Boninsegni P, Domenico Mediati R, Raffaele De Gaudio A.

Clin Drug Investig. 2009;29 Suppl 1:25-30. doi: 10.2165/0044011-200929001-00004.

PMID:
19445552
34.

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.

Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, Zucchetti M, D'Incalci M, Locatelli A, Marsoni S, Corradino I, Minoia C, Zintl P, Gianni L.

Eur J Cancer. 2009 Aug;45(12):2116-22. doi: 10.1016/j.ejca.2009.04.002. Epub 2009 May 4.

PMID:
19419856
35.

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.

Sessa C, Perotti A, Noberasco C, De Braud F, Gallerani E, Cresta S, Zucchetti M, Viganò L, Locatelli A, Jimeno J, Feilchenfeldt JW, D'Incalci M, Capri G, Ielmini N, Gianni L.

Eur J Cancer. 2009 May;45(7):1153-61. doi: 10.1016/j.ejca.2008.11.019. Epub 2008 Dec 27.

PMID:
19114300
36.

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.

Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, Bertoni F, Viganò L, Maur M, Capri G, Maccioni E, Tosi D, Gianni L.

Eur J Cancer. 2008 Sep;44(13):1829-34. doi: 10.1016/j.ejca.2008.05.022. Epub 2008 Jul 17.

PMID:
18640031
37.

Identification of new HIV-1 Gag-specific cytotoxic T lymphocyte responses in BALB/c mice.

Cellini S, Fortini C, Gallerani E, Destro F, Cofano EB, Caputo A, Gavioli R.

Virol J. 2008 Jul 14;5:81. doi: 10.1186/1743-422X-5-81.

38.

The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS.

Gavioli R, Cellini S, Castaldello A, Voltan R, Gallerani E, Gagliardoni F, Fortini C, Cofano EB, Triulzi C, Cafaro A, Srivastava I, Barnett S, Caputo A, Ensoli B.

Vaccine. 2008 Jan 30;26(5):727-37. Epub 2007 Dec 4.

PMID:
18096278
39.

Axillary apocrine carcinoma with brain metastases.

Gallerani E, Ciriolo M, Rossini C, Cavalli F.

J Clin Oncol. 2007 Dec 10;25(35):5655-6. No abstract available.

PMID:
18065737
40.

Acute left ventricular dysfunction due to Tako-tsubo syndrome after induction of general anesthesia.

Consales G, Campiglia L, Michelagnoli G, Gallerani E, Rinaldi S, Del Pace S, De Gaudio AR.

Minerva Anestesiol. 2007 Dec;73(12):655-8.

41.

Thrombotic thrombocytopenic purpura associated with renal failure after autologous transplantation for multiple myeloma successfully treated with rituximab.

Gallerani E, Lerch E, Romagnani E, Stathis A, Giardelli G, Zwhalen H, Marone C, Cavalli F.

Eur J Haematol. 2006 Dec;77(6):527-9. Epub 2006 Oct 17.

PMID:
17042766
42.

Mediastinal mature teratoma with an immature component--what about the treatment?

Romagnani E, Gallerani E, Cavalli F.

Ann Oncol. 2006 Oct;17(10):1602-4. Epub 2006 May 25. No abstract available.

PMID:
16728484
43.

Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1.

Remoli AL, Marsili G, Perrotti E, Gallerani E, Ilari R, Nappi F, Cafaro A, Ensoli B, Gavioli R, Battistini A.

Biochem J. 2006 Jun 1;396(2):371-80.

44.

A-line autoregression index monitoring to titrate inhalational anaesthesia: effects on sevoflurane consumption, emergence time and memory.

Rinaldi S, Consales G, Gallerani E, Ortolani O, De Gaudio AR.

Acta Anaesthesiol Scand. 2005 May;49(5):692-7.

PMID:
15836686
45.

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity.

Gavioli R, Gallerani E, Fortini C, Fabris M, Bottoni A, Canella A, Bonaccorsi A, Marastoni M, Micheletti F, Cafaro A, Rimessi P, Caputo A, Ensoli B.

J Immunol. 2004 Sep 15;173(6):3838-43.

46.

Treatment of liver metastases from colorectal cancer: what is the best approach today?

Biasco G, Gallerani E.

Dig Liver Dis. 2001 Jun-Jul;33(5):438-44. Review.

PMID:
11529658
47.

Partial characterization of SUVi, a new mammalian gene induced by UV-C and expressed during the S phase of the cell cycle.

Viaggi S, Gallerani E, Molina F, Nuesse M, Fronza G, Ottaggio L, Campomenosi P, Abbondandolo A, Menichini P.

Environ Mol Mutagen. 2001;37(1):76-84.

PMID:
11170244
48.

A gene trap approach to isolate mammalian genes involved in the cellular response to genotoxic stress.

Menichini P, Viaggi S, Gallerani E, Fronza G, Ottaggio L, Comes A, Ellwart JW, Abbondandolo A.

Nucleic Acids Res. 1997 Dec 1;25(23):4803-7.

49.

Sister chromatid exchange induction in peripheral blood lymphocytes of traffic police workers.

Bolognesi C, Gallerani E, Bonatti S, De Ferrari M, Fontana V, Valerio F, Merlo F, Abbondandolo A.

Mutat Res. 1997 Nov 27;394(1-3):37-44.

PMID:
9434841
50.

Aflatoxin exposure and cytogenetic alterations in individuals from the Gambia, West Africa.

Miele M, Donato F, Hall AJ, Whittle H, Chapot B, Bonatti S, De Ferrari M, Artuso M, Gallerani E, Abbondandolo A, Montesano R, Wild CP.

Mutat Res. 1996 Feb 1;349(2):209-17.

PMID:
8600352

Supplemental Content

Loading ...
Support Center